# **SPECTRE-study**

No registrations found.

**Ethical review** Positive opinion **Status** Recruitment stopped

Health condition type -

**Study type** Observational non invasive

## **Summary**

#### ID

NL-OMON21436

Source

NTR

**Brief title** 

**SPECTRE** 

**Health condition** 

Barrett's esophagus, esophageal cancer, field cancerization

## **Sponsors and support**

**Primary sponsor:** Academic Medical Center (AMC) Amsterdam **Source(s) of monetary or material Support:** KWF grant

### Intervention

#### Outcome measures

### **Primary outcome**

The primary objective of our study is to evaluate the feasibility of using MDSFR combined with OCT for the detection of field cancerization in Barrett esophagus patients.

### **Secondary outcome**

The secondary objective is to investigate the biological background of field cancerization detected by ESS

## **Study description**

### **Background summary**

Barrett's esophagus (BE) is a precursor lesion for esophageal adenocarcinoma. Therefore, the current Barrett's surveillance protocol consists of white light endoscopy and random biopsies. Field cancerization is based on the concept that focal cancers arise in tissue areas with random genetic changes. Light scattering spectroscopy might be able to detect this field cancerization and therefore be an innovative approach to improve detection of prevalent neoplasia in BE patients.

In this study, we will evaluate the feasibility of optical detection of field cancerization in BE patients.

### Study objective

Screening of esophageal cancer can be improved by the optical detection of field cancerization

### Study design

not applicable

#### Intervention

Optical measurements will be performed on several locations in the esophagus. Biopsies will also be obtained. Brush cytology will be obtained.

## **Contacts**

#### **Public**

Academic Medical Center<br/>
Bldg. C2-210, Meibergdreef J.J.G.H.M. Bergman Amsterdam 1105 AZ The Netherlands +31 (0)20 5669111

#### Scientific

Academic Medical Center<br/>
Bldg. C2-210, Meibergdreef J.J.G.H.M. Bergman Amsterdam 1105 AZ The Netherlands +31 (0)20 5669111

# **Eligibility criteria**

### **Inclusion criteria**

- Age > 18 years.
- Known BE, defined as columnar lined epithelium of the esophagus containing intestinal metaplasia upon biopsy.
- Signed informed consent.

### **Exclusion criteria**

- Contraindications for ER and/or obtain biopsies (e.g. due to anticoagulation, coagulation disorders, esophageal varices).
- Presence of an advanced lesion (e.g. type 0-I or type 0-III) not amendable for endoscopic resection (T1b).
- Presence of erosive esophagitis (Los Angeles classification ¡ÝA).
- Unable to provide signed informed consent.

# Study design

## Design

Study type: Observational non invasive

Intervention model: Other

Allocation: Non controlled trial

Masking: Open (masking not used)

Control: N/A, unknown

### Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 04-04-2016

Enrollment: 60

Type: Actual

### **IPD** sharing statement

Plan to share IPD: Undecided

## **Ethics review**

Positive opinion

Date: 15-03-2016

Application type: First submission

# **Study registrations**

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register ID

NTR-new NL5628 NTR-old NTR5735

Other AMC METC 2015\_323 : AMC METC 2015\_323

## **Study results**

### **Summary results**

None yet